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N this issue of the 
 
Journal,
 
 the results of the By-
pass Angioplasty Revascularization Investigation
(BARI), a large clinical trial comparing coronary-
artery bypass grafting (CABG) with percutaneous
transluminal coronary angioplasty (PTCA), are pre-
sented.
 
1
 
 BARI enrolled 1829 patients who were fol-
lowed for an average of 5.4 years. The authors con-
cluded that for patients with multivessel coronary
artery disease and suitable anatomy who prefer to
avoid major surgery, “angioplasty offers a reasonable
alternative with an expectation of similar overall sur-
vival rates and survival rates free of Q-wave myocar-
dial infarction.”
This carefully worded conclusion is similar to that
derived from a recent meta-analysis of eight smaller
trials with a total of 3371 patients with single-vessel
coronary disease (732 patients) or multivessel dis-
ease (2639 patients) followed for 1 to 4.7 years.
 
2
 
Readers may interpret these collective data to mean
that PTCA and CABG have equivalent outcomes.
The choice of procedure for individual patients may
then be based on other factors, such as shorter hos-
pital stays and avoidance of major surgery with
PTCA, or lower rates of subsequent procedures and
recurrent angina after CABG.
 
1-6
 
 But is such a simple
conclusion acceptable?
The aim of BARI was to determine whether an
initial strategy of PTCA, as compared with CABG,
compromises clinical outcome.
 
7
 
 The primary end
point was mortality at five years, which was found
to be 13.7 percent for PTCA and 10.7 percent for
CABG. The observed survival advantage at five years
with CABG was 2.9 percentage points, with a 95
percent confidence interval of 
 

 
0.2 to 6.0.
 
1
 
 Thus,
the study did not establish with certainty that an ini-
tial strategy of PTCA is actually equivalent to CABG
in patients with multivessel disease and clinically se-
vere angina or objective evidence of ischemia. In
fact, the confidence interval is consistent with the
possibility that the survival rate with CABG may be
superior by as much as 6 percentage points. Stated
differently, the data are consistent with a 50 percent
higher mortality rate with PTCA.
Although not statistically significant, a somewhat
higher mortality rate with PTCA was also reported
in two other trials, the Emory Angioplasty Versus
Surgery Trial (EAST)
 
5
 
 and the Coronary Angioplas-
ty versus Bypass Revascularization Investigation.
 
8
 
Combining all available data,
 
1,2
 
 my colleagues and I
calculated the risk ratios for mortality to be 1.25 (95
I
 
percent confidence interval, 0.75 to 2.07) at hos-
pital discharge (favoring PTCA), 0.86 (95 percent
confidence interval, 0.63 to 1.16) at one year, and
0.89 (95 percent confidence interval, 0.74 to 1.08)
overall (favoring CABG). These differences are not
statistically significant, and the confidence intervals
are wide, because the total number of patients in
these studies was limited. Thus, although a survival
advantage with CABG is suggested, there is insuffi-
cient statistical power to be certain. 
The relevance of small differences in survival may
be questioned. Yet differences of similar relative and
absolute magnitude have been reported in larger tri-
als claiming important treatment benefits for pa-
tients with moderately elevated cholesterol levels or
myocardial infarction. If differences in mortality on
the order of 1 percent (10 deaths per 1000 patients
treated) are considered relevant, larger trials are re-
quired to exclude such differences and to demon-
strate equivalence.
 
9
 
 It is remarkable that such larger
trials are commonly conducted for medical treat-
ment regimens, whereas comparative trials of inter-
ventional procedures such as BARI do not have suf-
ficient statistical power to demonstrate or exclude
similar differences. Furthermore, the difference be-
tween treatment regimens, if any, may become ap-
parent only after long-term follow-up.
In BARI, myocardial infarction during the initial
hospitalization was more frequent after CABG than
after PTCA. Nevertheless, the rates of survival free
from Q-wave myocardial infarction (80.4 percent af-
ter CABG and 78.7 percent after PTCA) were simi-
lar at five years.
 
1
 
 The investigators correctly point
out that the rates of infarction were underestimated,
because only Q-wave myocardial infarctions were re-
ported. This explains why the rates are lower than
those in other recent trials in which serum creatine
kinase MB values were used to detect infarctions
associated with PTCA.
 
7
 
 The interpretation of a com-
posite end point, such as survival without myocar-
dial infarction, becomes difficult if the various com-
ponents are not affected in the same way. How
should we interpret the somewhat better survival in
spite of somewhat more frequent myocardial infarc-
tions with CABG in BARI? Clearly, in this situation,
more weight should be given to the survival advan-
tage, albeit small. It is better to survive with an in-
farct than not to survive at all.
In BARI, as in the other studies, CABG provided
more extensive revascularization, with an average of
3.1 grafts per patient, than PTCA, for which angio-
plasty was attempted for an average of 2.4 lesions.
 
10
 
This difference, along with the problem of resteno-
sis, resulted in higher rates of angina and repeated
revascularization procedures after PTCA.
 
1-6
 
 
A subgroup analysis in BARI revealed a major ad-
vantage of CABG over PTCA in patients with treat-
ed diabetes. In fact, the higher mortality after PTCA
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(as compared with CABG) was accounted for by the
higher rate in this subgroup of patients, which made
up 19 percent of the study population. This impor-
tant observation would have major implications for
therapy in clinical practice if confirmed by data from
other trials. However, in EAST, the mortality rate
among diabetics in the PTCA group was not higher
than in the CABG group,
 
5
 
 although this population
was much smaller. Additional analyses from the oth-
er trials may help to clarify this issue.
Many factors influence the choice of procedure
for revascularization in a given patient (Table 1).
The decision by the physician and the patient will
depend on the weight given to the various factors.
In studies of interventional procedures, technolo-
gy may change during the long interval between the
enrollment of patients and the reporting of results.
Consequently, the results of a trial may apply to
procedures that are not fully comparable to those
used currently. Indeed, major advances have been
made in interventional cardiology. The use of block-
ers of platelet glycoprotein IIb/IIIa receptors may
halve the rate of periprocedural myocardial infarc-
tion and improve long-term outcome.
 
7
 
 Furthermore,
the use of coronary stents improves outcome, par-
ticularly since the introduction of better deployment
techniques, better antithrombotic regimens, and hep-
arin-coated stents.
 
11
 
 Also, surgical techniques contin-
ue to improve with more frequent use of internal-
thoracic-artery grafts and, more recently, minimally
invasive surgical procedures.
 
12
 
In the past, CABG and PTCA were distinct pro-
cedures performed by separate groups of operators.
In the near future we may expect more of a team
approach and the development of larger revascular-
ization centers in which different procedures are
performed by a closely coordinated team of opera-
tors with different backgrounds. Such developments
necessitate repeated reassessment of the relative
strengths and weaknesses of surgical and percutane-
ous revascularization procedures. Studies of ade-
quate size remain warranted in spite of the findings
in BARI and other comparisons of coronary surgery
and angioplasty.
 
1-6
 
 In the meantime, the conclusions
of the BARI investigators stand: in patients with
myocardial ischemia and multivessel disease, who
constitute 12 percent of all candidates for revascu-
larization, surgery is the established therapy, and an-
gioplasty is an acceptable alternative.
 
M
 
AARTEN
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Thoraxcenter, Erasmus University
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BETWEEN
 
 CABG 
 
AND
 
 PTCA.
 
CABG PTCA
 
ADVANTAGES DISADVANTAGES ADVANTAGES DISADVANTAGES
 
Established Differences
 
Results in more complete 
revascularization
Provides excellent relief of 
angina
Associated with fewer sub-
sequent procedures
Involves major surgery 
(possible perioperative 
problems)
Requires longer hospital-
ization and higher initial 
costs
Major surgery avoided in 70 
percent of patients 
Associated with shorter hospi-
talization and lower initial 
costs
Results in less complete
revascularization
Angina may recur
Associated with more 
subsequent proce-
dures
 
Possible Differences
 
Possibly better long-term 
survival
Associated with more early 
infarctions
Associated with fewer peripro-
cedural infarctions
Possibly poorer long-
term survival
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F all the medical disorders that add risk to preg-
nancy, renal disease has long ranked among
those most feared by physicians. Not only are the re-
nal and vascular manifestations of preeclampsia the
most common medical complication of pregnancy,
affecting 5 to 7 percent of previously healthy wom-
en, but also intrapartum worsening of renal func-
tion, along with increased fetal morbidity and mor-
tality, has been the fate of a large proportion of
pregnant women with underlying diseases of the
kidney, at least in the past.
 
1
 
 Careful longitudinal
studies of large numbers of women with varying de-
grees of renal impairment are necessary to permit us
to advise concerned patients intelligently about the
risks of pregnancy. The results of the study by Jones
and Hayslett of 82 pregnancies in 67 women with
moderate or severe renal insufficiency, reported in
this issue of the 
 
Journal,
 
2
 
 will help obstetricians and
internists do just that. Such data are not easy to col-
lect, because fertility is decreased in women with re-
nal impairment.
For doctors who need to counsel women with re-
nal impairment who are contemplating pregnancy,
certain caveats must be kept in mind in interpreting
these results. First, some women who do well may
be lost to follow-up after pregnancy because they
do not seek medical advice. On the other hand,
longitudinal surveys of the outcome of pregnancy
cannot include women who contemplated pregnan-
cy but did not in fact become pregnant, perhaps
on their doctors’ advice. Such women may have a
poorer prognosis than those who actually become
pregnant.
The good news in this report is that with advances
in the care of newborn babies, fetal survival has im-
proved remarkably. This is important because almost
60 percent of infants born to women with a serum
creatinine concentration exceeding 1.4 mg per dec-
iliter (124 
 
m
 
mol per liter) are premature — six times
the expected rate in the general population — and
because the babies are also small for their gestational
age. Both problems are more marked, the worse the
mother’s renal insufficiency. Nevertheless, fetal mor-
tality in the present report was only 7 percent, as
compared with rates ranging from 12 to 88 percent
O
 
in earlier, smaller series of similar women.
 
3-6
 
 With
the advent of modern intensive care for newborns,
survival is routine even when babies are born as early
as 26 to 27 weeks of gestation.
The news is not so good for the mother. What is
clear from all the published data is that, as the wom-
an’s degree of renal insufficiency increases, the risk
that renal function will worsen during pregnancy ris-
es sharply, a tendency that is further exaggerated by
the presence of hypertension. Katz et al. found that
renal function declined during pregnancy in 16 per-
cent of women with mild renal disease (those with
initial serum creatinine concentrations of less than
1.4 mg per deciliter), most of whom were normo-
tensive.
 
7
 
 Of the women followed by Jones and Hays-
lett whose initial serum creatinine concentrations
were 1.4 mg per deciliter or more, almost half had a
pregnancy-related decline in creatinine clearance of
at least 25 percent, and in three quarters of these
women, the decline in renal function persisted or
progressed further after delivery. Among women
whose initial serum creatinine concentrations were
between 1.4 and 1.9 mg per deciliter (124 and 168
 
m
 
mol per liter), the chance of a pregnancy-related
exacerbation was roughly 40 percent, and the loss of
renal function persisted after delivery in about half
of those affected. 
The risk of pregnancy-related renal damage was
found to be particularly high in the subgroup of
women whose initial serum creatinine concentra-
tions were 2.0 mg per deciliter (177 
 
m
 
mol per liter)
or higher. Of 20 pregnancies in such women, serum
creatinine concentrations rose in the third trimester
in 13 (65 percent). Worsened renal function persist-
ed or progressed after delivery in almost all these
women, rapidly reaching end-stage renal failure in
seven (35 percent). Thus, unlike pregnancy in wom-
en with only mild renal disease, pregnancy in women
with moderate or severe renal disease tends to exac-
erbate renal injury in a way that is largely irreversible.
This conclusion is supported not only by the data of
Jones and Hayslett, but also by earlier studies involv-
ing smaller numbers of women.
 
3-6
 
 Although some of
the late decline in kidney function may be attributed
to the natural progression of the underlying disease,
it is notable that in the present study all the women
with peripartum worsening for whom preconcep-
tion data were available had decreases in the glomer-
ular filtration rate during pregnancy that exceeded
those predicted.
There are, of course, exceptions to the general
rule. One of the study patients had an initial serum
creatinine concentration of 3.7 mg per deciliter
(327 
 
m
 
mol per liter) and had no change in renal
function either during pregnancy or six weeks after
delivery. Many nephrologists and obstetricians can
recount such anecdotes. An optimistic physician or
a woman yearning to bear a child may prefer to view
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the glass as half full. But a sober analysis of all the
risks involved in pregnancy for a woman with renal
impairment should include a realistic assessment of
the dangers of worsening renal function. What data
we have indicate that a pregnant woman with a se-
rum creatinine concentration exceeding 2.0 mg per
deciliter has a chance of approximately one in three
of having end-stage renal failure necessitating dialy-
sis during or shortly after pregnancy. The chances
are better than even that renal function will be worse
after the pregnancy than it would have been if preg-
nancy had been avoided. Manifestations of pre-
eclampsia in susceptible women with renal disease
may be reduced somewhat by treatment with low
doses of aspirin,
 
8
 
 but this treatment is still contro-
versial.
 
9
 
Why does pregnancy exacerbate renal disease?
One notion is that the worsening is paradoxically re-
lated to the increase in glomerular perfusion charac-
teristic of normal pregnancy. But this hypothesis
seems contradicted by the facts at hand. Most wom-
en whose renal function deteriorates during preg-
nancy have no evidence of early hyperperfusion,
such as an initial fall in the serum creatinine concen-
tration.
A more attractive hypothesis is that the preexist-
ing renal disease somehow sets the stage for the cas-
cade of platelet aggregation, formation of fibrin
thrombi, microvascular coagulation, and endothelial
dysfunction in the kidney and elsewhere that is at
the heart of the phenomenon of preeclampsia. An
imbalance between the production of vasoconstric-
tor products of arachidonic acid (thromboxane) and
vasodilatory ones (prostacyclin) has long been pos-
ited in preeclampsia. It may be important that renal
overproduction of thromboxane is regularly elicited
by experimental renal insufficiency.
 
10
 
 The consequent
superimposition of preeclamptic microangiopathy on
already-damaged kidneys might cause poorly revers-
ible or persistent renal damage in some women. Fur-
ther collaborative studies of these phenomena by ne-
phrologists and obstetricians should provide clearer
insights into both the physiology of pregnancy and
the nature of renal disease.
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N 1993, a National Institutes of Health Consen-
sus Conference declared infection with 
 
Helico-
bacter pylori
 
 to be an important cause of duodenal
and gastric ulcers.
 
1
 
 Soon thereafter, the Internation-
al Agency for Research on Cancer classified 
 
H. pylori
 
as a group 1 carcinogen, a definite cause of gastric
adenocarcinoma in humans.
 
2
 
 In this issue of the
 
Journal,
 
 Hansson and colleagues report that patients
with duodenal ulcers have a decreased risk of gastric
cancer, whereas those with gastric ulcers have an in-
creased risk.
 
3
 
 Thus, a paradox in the epidemiology
of gastric disease is unmasked. The incidence of gas-
tric cancer correlates positively with the incidence of
gastric ulcer but negatively with the incidence of
duodenal ulcer.
 
4
 
 If 
 
H. pylori
 
 causes each of these dis-
eases, why is it that they do not all occur in parallel?
 
H. pylori
 
 is a highly successful microbe, infecting
most of the world’s population. Once established
in the stomach, the organism persists for decades,
seemingly impervious to the acid and peristaltic ac-
tivity in its environment. In most cases, 
 
H. pylori
 
 si-
lently coexists with its host, causing no symptoms
or signs. But this relation is not always benign. Gas-
tric cancer develops in approximately 1 percent of
infected persons, and 20 percent have duodenal ul-
cers. The findings of Hansson et al. argue that sep-
arate paths lead to these diseases — that is, 
 
H. pylori
 
infection can progress to gastric cancer or duodenal
ulcer but seldom to both. This being the case, other
factors besides the infection must foster one disease
while militating against the other. Examples of po-
tentially important cofactors are the genetic charac-
teristics of the host and the microorganism; exoge-
nous elements, either infectious or noninfectious;
and the time of life when the infection is acquired
— early in childhood or later. All these undoubted-
I
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ly influence the outcome of 
 
H. pylori
 
 infection, but
the last best explains the paradox reported by Hans-
son et al.
Gastric cancer is a leading cause of death from
cancer in the developing world, where infection with
 
H. pylori in early childhood is the rule.5 In infected
children, duodenal ulcer is rare. However, by early
adulthood, the infection acquired in childhood has
frequently progressed to multifocal atrophic gastri-
tis, a pathologic condition characterized by patchy
loss of gastric glands that secrete protein and acid.6
By mechanisms as yet unknown, multifocal atrophic
gastritis and the associated hypochlorhydria predis-
pose patients to both gastric ulcers and cancer. In
contrast, duodenal ulcers are rare in patients with
multifocal atrophic gastritis, since even in the pres-
ence of H. pylori, the precept “no acid, no ulcer”
holds. In short, childhood infection predisposes pa-
tients to gastric ulcers and stomach cancer, but it in-
hibits the development of duodenal ulcers.
In industrialized countries, deaths due to gastric
cancer, gastric ulcers, and duodenal ulcers are de-
creasing.7,8 As might be expected, these declines par-
allel a diminishing incidence of H. pylori infection,
particularly in children.9 Thus, the prevalence of in-
fection is declining, and the average age at the time
infection is acquired is rising. Multifocal atrophic
gastritis is uncommon when infection occurs after
childhood. It may still occur, but at older ages, a
change that has the effect of pushing back by five
years the age at which gastric cancer is diagnosed
in industrialized countries.9 In young adults, acid-
secreting capacity is maintained in the face of muco-
sal damage caused by H. pylori, and duodenal ulcer
disease is endemic. 
This age-dependent explanation of the outcomes
of H. pylori infection fits the temporal pattern of
gastric diseases described by Sonnenberg.7 Among
people born before the Industrial Revolution, both
gastric cancer and duodenal ulcers would have been
unusual. Their short life expectancy would have
limited the incidence of gastric cancer, and high
rates of H. pylori infection in children would have
limited the incidence of duodenal ulcers by causing
the early onset of multifocal atrophic gastritis. For
cohorts born during the Industrial Revolution, hy-
giene in childhood remained poor and H. pylori in-
fection was almost universal in children.7 But at the
end of the 19th century, a rapid increase in life ex-
pectancy coincided with the highest mortality from
gastric ulcers and gastric cancer in the past 150
years. As hygiene and economic conditions gradu-
ally improved, the age at which H. pylori infection
was acquired in subsequent birth cohorts shifted
upward. Rates of gastric cancer correspondingly de-
clined. The incidence of duodenal ulcers, by con-
trast, increased and then decreased as the prevalence
of infection declined. In this way, the peak mortal-
ity due to duodenal ulcer disease followed the peak
mortality from gastric ulcers by one to two decades.
Today, the rates for all three diseases are declining
in parallel.
This model is inferential, but the effect of the age
of acquisition of H. pylori infection has been circum-
stantially confirmed. Larger families are a risk factor
for the transmission of diseases from person to per-
son. Children with many older siblings are more like-
ly to acquire infection at an earlier age than only
children or oldest children. In a study of Japanese-
American adults, late birth order and a large number
of siblings both increased the risk of gastric cancer,
but only among people with H. pylori infection.10 In
contrast, family size in childhood had no effect on
the incidence of duodenal ulcer disease, among ei-
ther infected or uninfected adults. Indirectly, then,
it appears that the rate of childhood infection with
H. pylori affects the incidence of gastric cancer but
not of duodenal ulcer.
One conclusion that should not be drawn from
the study of Hansson et al. is that duodenal ulcer it-
self protects against gastric cancer. Gastric cancers
do occur in patients with a history of duodenal ul-
cer, even when they have not undergone gastric
resection.11 This is so because patients with duode-
nal ulcers are not immune from late-onset multifocal
atrophic gastritis. Moreover, the risk of multifocal
atrophic gastritis in patients with duodenal ulcers
may be increasing. A recent study showed that pro-
ton-pump inhibitors, by altering the gastric micro-
environment, increased the rate of progression of
H. pylori gastritis to multifocal atrophic gastritis.12
In principle, current therapies might be advancing
the cancer clock by converting relatively benign
gastric inflammation into a more destructive, pre-
malignant process. At present, there is no convinc-
ing evidence that pharmacologic inhibition of acid
secretion increases the risk of gastric cancer, but the
long-term use of acid-inhibiting therapy in patients
with H. pylori infection should be viewed with some
caution.
The relation between H. pylori and humans is
evolving. In the past 200 years, gastric cancer, gastric
ulcer, and duodenal ulcer have waxed and waned. In
other parts of the world, diseases related to H. pylori
continue to pose important health burdens, but in
the United States, we are witnessing the decline of
H. pylori. Improvements in hygiene and economic
conditions have interfered with the transmission cy-
cle of the organism to the point where H. pylori is
now hard to find in children. Yet the worldwide
prevalence of infection remains high. Moreover, as
with shigella infections, crowded conditions in day-
care centers may again provide the opportunity for
early childhood transmission. The varying outcomes
of H. pylori infection serve to remind us that our in-
teractions with the microbial world are constantly in
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flux. A better understanding of these patterns will
enable us to anticipate and interrupt the long-term
consequences of this deleterious parasite–host inter-
action.
JULIE PARSONNET, M.D.
Stanford University School of Medicine
Stanford, CA 94305
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PHYSICAL AND EMOTIONAL PROBLEMS 
OF ELITE FEMALE GYMNASTS
ITHIN the past five years, two U.S. female
gymnasts at the Olympic level, Christy Hen-
rich and Julissa Gomez, died from medical problems
related to their sport. Christy died from complica-
tions of anorexia nervosa and Julissa from complica-
tions of spinal trauma due to a vaulting injury.
In this Olympic year, it is timely to discuss the
psychological and physical problems associated with
competitive women’s gymnastics. Women’s gymnas-
tics provides a useful framework for viewing worri-
some trends in other competitive youth sports. In
the United States, organized athletic programs in-
volve at least 20 million children and adolescents
each year, with more than 2 million participating in
all levels of competitive gymnastics.1,2
The development of gymnastics champions in-
volves hard training, stringent coaching, and often
parental pressure, ostensibly in the best interest of
the child. Overtraining, injuries, and psychological
damage are common consequences.3,4 Parents and
coaches, in collusion with the young athlete, may
seek to experience vicariously the success of the
child, a behavior that could be called “achievement
by proxy.” The recent death of seven-year-old Jessica
Dubroff during her abortive cross-country airplane
flight has been cited as a glaring illustration of this
behavior.5 Its hallmark is strong parental encourage-
ment of a potentially dangerous endeavor for the
purpose of gaining fame and financial reward. We
suggest that in its extreme form “achievement by
proxy” may be a sort of child abuse.
Elite gymnasts throughout the world begin train-
ing between the ages of five and seven years. They
are often involved in serious, regimented training by
the age of 10. During this critical stage of develop-
ment, children experience rapid physiologic, neuro-
logic, and psychological growth.3 Participation in
Olympic-level gymnastics may place inappropriate
physical and psychological demands on these chil-
dren, which may have long-term, indeed lifelong,
adverse consequences.6,7
PHYSICAL INJURIES
Gymnastics is an intense, repetitive, high-impact
sport, and most elite gymnasts do not pass through
childhood and adolescence without injury.4,8 The
W
risk of injury increases with longer practice time, the
degree of difficulty of the routines, and age-related
vulnerability of the skeletal system.1,3,6,9,10 Repetitive
stress on the developing musculoskeletal system,
which has a much higher cartilage content than in
adults, may cause an accumulation of minor physical
insults that can result in permanent injury or de-
formity.11,12 These injuries include stress fractures;
growth-plate fractures; wrist and elbow injuries;
spinal injuries such as scoliosis, spondylolysis, and
spondylolisthesis; and reflex sympathetic dystro-
phy.13,14 Moreover, training more than 18 hours per
week before and during puberty may alter the
growth rate and prevent the attainment of full adult
height.15,16
The pressure to practice and compete while in-
jured compounds the risk of impaired skeletal devel-
opment and permanent deformity.17,18 Overtraining
with incompletely healed injuries may contribute to
reflex sympathetic dystrophy. This is a disorder char-
acterized by an exaggerated response of the sympa-
thetic nervous system to minor trauma, resulting in
severe, recurrent, chronic pain affecting an entire leg
or arm, accompanied by autonomic nervous system
changes. Inactivity and inadequate treatment result
in muscle atrophy, bone demineralization, and con-
tractures.19,20 Psychological stress has been noted to
have a significant role in precipitating reflex sympa-
thetic dystrophy.19,20 
THE FEMALE-ATHLETE TRIAD
Gymnasts are also at risk for nutritional, endo-
crine, and psychiatric disorders. The “female-athlete
triad,” which is associated with substantial morbidi-
ty and mortality,21,22 is characterized by disordered
eating, menstrual dysfunction, and osteoporosis.21-23
In the general population, the prevalence of eating
disorders is about 1 percent for anorexia and 1 to
3 percent for bulimia.24 Among female athletes, how-
ever, the prevalence of eating disorders is reported
to be between 15 percent and 62 percent.14,22,25,26
There is unequivocal pressure for female gymnasts
to maintain a prototypic mesomorphic body appear-
ance (i.e., to be thin and muscular). This pressure
encourages atypical eating behavior, which may lead
to frank eating disorders.14,21,26,27 Oblique or delib-
erate comments by coaches or judges that the loss
of a few pounds will improve athletes’ scores may
exacerbate these problems.28,29 Judges have a pro-
found influence on the careers of gymnasts, and
they may indirectly contribute to the development
of eating disorders. Disordered eating and intensive
exercise may contribute to primary and secondary
amenorrhea.21,22,30,31 In addition to the physical
stress on the athlete, the emotional stress of elite
competition may play a part in the development of
menstrual dysfunction.32 Menstrual dysfunction, in
turn, increases the risk of premature osteoporosis
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and fractures22,30,33-35 and may also increase the risk
of scoliosis.36
ISSUES OF IDENTITY
There is enormous pressure — particularly from
adults — for the child gymnast to be thin and per-
form well in order to conform to and promote the
image of the sport.28 Adults are often seduced by
Olympic dreams and the lucrative opportunities that
success may bring.28,37 The young athlete may per-
ceive her entire identity and self-worth as depending
on her participation and success in gymnastics — a
perception that may result in a unidimensional self-
concept.38 As these youngsters mature, some realize
that what is happening to them is unhealthy. How-
ever, the highly organized and restrictive gymnastics
programs, as well as family pressures and expecta-
tions, impede the athlete’s ability to think or act in-
dependently.39 Pain, somatoform disorders, and self-
induced injury may become the only acceptable ways
to escape with one’s dignity (and the parent’s or
coach’s dignity and self-esteem) intact.40 
Many aspiring young gymnasts devote nearly all
of their time to the sport and may thereby suffer
from social isolation and a lack of opportunities for
social development.39 At the elite level, gymnasts
work out on average 30 to 45 hours per week.28,41
They may leave home before the age of 12 to train
and in some cases are adopted by their coaches. At
every competitive level, critical coaching with the
goal of winning is paramount.42 Young female gym-
nasts begin traveling extensively and staying in hotels
and are often expected to behave as independent
adults at a time when they may not even have en-
tered puberty. Parents and coaches often attribute a
child’s overtraining to the child’s enthusiasm and
love for the sport, but this may be little more than
self-deception and an abrogation of adult responsi-
bility.
ELITE GYMNASTICS
AND THE POTENTIAL FOR ABUSE
Elite gymnasts tend to be extremely obedient and
disciplined and to strive for adult approval. In gen-
eral, they are in awe of coaches and other adult au-
thorities, who hold the key to potential success; con-
sequently, they are at risk for abuse.28 Insensitivity
on the part of adults to a child’s developmental re-
quirements leads to an attempt to delay the onset of
puberty, on the one hand, and the attribution of
adult qualities to the child, on the other. Presenting
a prepubescent girl as sexually attractive in order to
gain higher scores is a matter of particular concern.
“After all,” as one judge said, “it is a very visual
sport.”28,29 The quest for success at the Olympic lev-
el ensures that these girls may be driven beyond
their physical and emotional limits. There is also an
element of self-abuse involved in competing in an
injured state. Sometimes physicians may also be-
come involved in the process of getting an injured
athlete back into competition too soon. Further in-
creasing the risk of abuse is the enormous sacrifice
and emotional investment made by entire families in
helping the athlete achieve the Olympic dream.41 The
personal and financial sacrifices of these families may
increase the stress on the child.39
Coaches, who may have the greatest influence
over athletes and their parents, are in the best posi-
tion to monitor the athlete’s behavior.43 Unfortu-
nately, most coaches have little knowledge of child
development, although gymnasts typically spend
more time with their coaches during these critical
developmental years than with any other person.
Coaches are often role models for these vulnerable
young girls, who strive to attain their mentors’ ap-
proval. Given coaches’ frequent lack of awareness of
developmental issues, unrealistic and unhealthy phys-
ical and psychological demands are often placed on
these children.
THE NEED FOR COACHING STANDARDS
Encouraging but modest efforts have been made
by the elite gymnastics community in monitoring it-
self.33,44 An example was the recently published pre-
liminary report of the Female Athlete Triad Task
Force.44 Officials of national gymnastics programs
are clearly concerned about the athletes’ well-being.
However, as members of governing bodies, they
have political and financial goals that are likely to be
in unavoidable conflict with the best interests of the
child athletes. An external agency may be needed to
establish standards and monitor health and safety re-
quirements for the athletes. External regulation in
conjunction with improved self-monitoring could
be a big step forward in protecting young competi-
tors.43,45
THE GOAL: PREVENTING HARM
TO ELITE ATHLETES
In this Olympic year, millions of spectators will be
treated to a dazzling display of elite women’s gym-
nastics in which the main medal contenders may all
be under the age of 16. It is important, however,
that we understand the human story that lies behind
this and other elite sports. At its best, elite gymnas-
tics can provide a profoundly meaningful experience
for the athletes, promoting their self-esteem and
self-discipline and contributing to their develop-
ment into productive and successful adults. At its
worst, the sport can result in serious, life-endanger-
ing physical and psychological disabilities. As physi-
cians, we need to remember that the development,
health, and well-being of these gifted children must
be assigned the highest priority. “Achievement by
proxy” on the part of parents, coaches, and other
adults (sometimes even physicians) can pose real dan-
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gers to the health of these vulnerable young girls.
Talented youngsters at every competitive level should
be supported rather than crippled by their sport as
they enter adulthood.
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